Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1700190

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions her Department has had with the Department for Science, Innovation and Technology on funding for (a) the Lobular Moon Shot Project and (b) other research into lobular breast cancer.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	21157
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department invests £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). We work closely with UK Research and Innovation (UKRI) and the Medical Research Council (MRC), who are responsible for channelling a large proportion of the Department for Science, Innovation and Technology’s investments in this area. Our officials meet regularly to discuss a wide range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. While research to understand the mechanisms of cancer, including lobular breast cancer, is largely funded through UKRI and the MRC, the NIHR invests in translational and implementation research to drive innovations into policy and practice.</p><p> </p><p>Launched in 2023, the Lobular Moonshot Project is a high-level funding proposal and campaign to raise money to support the Institute for Cancer Research (ICR), with whom we meet regularly, to invest in fellowships and projects in lobular breast cancer. We are proud to have invested £29 million in the ICR and Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, again including lobular breast cancer. This is complemented by wider investments into breast cancer research, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, such as lobular breast cancer. Our support to the NIHR Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.</p><p> </p><p>Additionally, the NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years, the CRN has supported delivery of 10 lobular breast cancer-related studies conducted by other partners. While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, treatment, and care, which saves lives.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21158 question first answered 22/04/2024 14:13:15 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1700191

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to provide support to the Lobular Breast Cancer Project.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	21158
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department invests £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). We work closely with UK Research and Innovation (UKRI) and the Medical Research Council (MRC), who are responsible for channelling a large proportion of the Department for Science, Innovation and Technology’s investments in this area. Our officials meet regularly to discuss a wide range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. While research to understand the mechanisms of cancer, including lobular breast cancer, is largely funded through UKRI and the MRC, the NIHR invests in translational and implementation research to drive innovations into policy and practice.</p><p> </p><p>Launched in 2023, the Lobular Moonshot Project is a high-level funding proposal and campaign to raise money to support the Institute for Cancer Research (ICR), with whom we meet regularly, to invest in fellowships and projects in lobular breast cancer. We are proud to have invested £29 million in the ICR and Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, again including lobular breast cancer. This is complemented by wider investments into breast cancer research, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, such as lobular breast cancer. Our support to the NIHR Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.</p><p> </p><p>Additionally, the NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years, the CRN has supported delivery of 10 lobular breast cancer-related studies conducted by other partners. While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, treatment, and care, which saves lives.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21157 question first answered 22/04/2024 14:13:15 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1700192

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much funding has been provided for research into (a) lobular breast cancer and (b) other forms of breast cancer in each of the last five years.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	21159
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department is proud to invest £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). Department officials meet regularly to discuss a wide-range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. The NIHR invests in translational and implementation research to drive innovations into policy and practice.</p><p>We are proud to have invested £29 million into the Institute of Cancer Research (ICR) and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. This is complemented by wider investments into breast cancer research including, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, again including lobular breast cancer. Our support to the NIHR’s Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.</p><p>While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, and treatment and care, which saves lives.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:01:55 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1700221

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Greater London
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the level of stocks of epilepsy medication in south London pharmacies as of 12 April 2024.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	21164
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department has a role to play in ensuring that supplies of medicines are available nationally, and in sufficient quantity to meet demand. The Department does not monitor stocks of medicine at a local level, and as such no assessment has been made of the level of stocks of epilepsy medication in South London pharmacies.</p><p>The Department has been working intensively with the pharmaceutical industry, National Health Service, and others to address issues with the supply of some epilepsy medications. As a result of our action, some supply issues with Tegretol prolonged-release tablets have been resolved. However, some issues remain, and we are working with suppliers to resolve these as soon as possible by expediting future deliveries, and ensuring that alternative products remain available. We have issued guidance to healthcare professionals on how to manage patients requiring affected medicines while supply is disrupted. The Department has been engaging with the Epilepsy Society to keep them updated on developments.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21165 question first answered 22/04/2024 15:57:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1700222

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Greater London
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase supplies of epilepsy medication in south London.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	21165
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department has a role to play in ensuring that supplies of medicines are available nationally, and in sufficient quantity to meet demand. The Department does not monitor stocks of medicine at a local level, and as such no assessment has been made of the level of stocks of epilepsy medication in South London pharmacies.</p><p>The Department has been working intensively with the pharmaceutical industry, National Health Service, and others to address issues with the supply of some epilepsy medications. As a result of our action, some supply issues with Tegretol prolonged-release tablets have been resolved. However, some issues remain, and we are working with suppliers to resolve these as soon as possible by expediting future deliveries, and ensuring that alternative products remain available. We have issued guidance to healthcare professionals on how to manage patients requiring affected medicines while supply is disrupted. The Department has been engaging with the Epilepsy Society to keep them updated on developments.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21164 question first answered 22/04/2024 15:57:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes